[Histopathological and immunohistochemical studies on the elevation mechanism of cancer associated antigens, CEA and CA19-9, in patients with colorectal cancer]. 1988

H Deguchi, and Y Tabuchi, and Y Saitoh
First Department of Surgery, Kobe University School of Medicine, Japan.

Correlation between CEA and CA19-9 levels of peripheral and draining venous blood, and 12 histopathologic and immunohistochemical variables, was examined in 108 patients with colorectal cancer. CEA levels of draining blood (mean 62.7 ng/ml and positive rate greater than 5 ng/ml, 63.9%) were significantly higher than those (16.3 ng/ml and 31.5%) of peripheral blood. However, CA19-9 levels (mean 576 U/ml and positive rate greater than 37 U/ml, 29.5%) of draining blood were not different from those (568.0 U/ml and 29.5%) of peripheral blood. Histochemically, CEA was observed in all of the 83 specimens and distributed in almost of all cancer cells, although CA19-9 was found in 52 (62.5%) of 83 specimens and focally localized in some part of cancer lesions. Elevation of CEA levels in draining and peripheral blood was most highly correlated with grade of venous invasion and its layer of colorectal wall. While, elevation of CA19-9 levels in both draining and peripheral blood was most highly associated with grade of lymphatic invasion and node metastasis. CEA levels of peripheral blood was negative in 9 (47.4%) of 19 patients with liver metastasis. However, the levels of draining blood was negative only one (5.3%) of these patients and the mean value (273.6 ng/ml) was much greater than that (59.6 ng/ml) of peripheral blood. These results suggest that CEA may be haematogenously drained by the portal system via the draining vein from the cancer cells in the invasive veins, and that CA19-9 may be drained by the thoracic duct of lymphatic system. It is also suggested that the measurement of CEA, especially in draining blood, and CA19-9 may be available to predict the metastasis and/or recurrence of different organs such as the liver, lymph node and so on.

UI MeSH Term Description Entries
D012004 Rectal Neoplasms Tumors or cancer of the RECTUM. Cancer of Rectum,Rectal Cancer,Rectal Tumors,Cancer of the Rectum,Neoplasms, Rectal,Rectum Cancer,Rectum Neoplasms,Cancer, Rectal,Cancer, Rectum,Neoplasm, Rectal,Neoplasm, Rectum,Rectal Cancers,Rectal Neoplasm,Rectal Tumor,Rectum Cancers,Rectum Neoplasm,Tumor, Rectal
D002272 Carcinoembryonic Antigen A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment. Antigens, CD66e,CD66e Antigen,Antigen, CD66e,Antigen, Carcinoembryonic,CD66e Antigens
D003110 Colonic Neoplasms Tumors or cancer of the COLON. Cancer of Colon,Colon Adenocarcinoma,Colon Cancer,Cancer of the Colon,Colon Neoplasms,Colonic Cancer,Neoplasms, Colonic,Adenocarcinoma, Colon,Adenocarcinomas, Colon,Cancer, Colon,Cancer, Colonic,Cancers, Colon,Cancers, Colonic,Colon Adenocarcinomas,Colon Cancers,Colon Neoplasm,Colonic Cancers,Colonic Neoplasm,Neoplasm, Colon,Neoplasm, Colonic,Neoplasms, Colon
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000951 Antigens, Neoplasm Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin. Neoplasm Antigens,Tumor Antigen,Tumor Antigens,Antigen, Tumor,Antigens, Tumor
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D015295 Antigens, Tumor-Associated, Carbohydrate Carbohydrate antigens expressed by malignant tissue. They are useful as tumor markers and are measured in the serum by means of a radioimmunoassay employing monoclonal antibodies. Antigens, Carbohydrate, Tumor-Associated,CA Antigens,Cancer-Associated Carbohydrate Antigens,Carbohydrate Antigens, Tumor-Associated,Tumor-Associated Carbohydrate Antigens,Antigen, Carcinoma-Associated,CA Antigen,CA(Oxford) Antigen,Carcinoma-Associated Antigen,Epitectin,Antigen, CA,Antigen, Carcinoma Associated,Antigens, CA,Antigens, Cancer-Associated Carbohydrate,Antigens, Tumor-Associated Carbohydrate,Cancer Associated Carbohydrate Antigens,Carbohydrate Antigens, Cancer-Associated,Carbohydrate Antigens, Tumor Associated,Carcinoma Associated Antigen,Tumor Associated Carbohydrate Antigens

Related Publications

H Deguchi, and Y Tabuchi, and Y Saitoh
April 2021, Clinical laboratory,
H Deguchi, and Y Tabuchi, and Y Saitoh
April 2021, Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine],
H Deguchi, and Y Tabuchi, and Y Saitoh
January 1997, Anticancer research,
H Deguchi, and Y Tabuchi, and Y Saitoh
November 2017, HPB : the official journal of the International Hepato Pancreato Biliary Association,
H Deguchi, and Y Tabuchi, and Y Saitoh
March 2021, Diseases (Basel, Switzerland),
H Deguchi, and Y Tabuchi, and Y Saitoh
January 1990, Journal of gastroenterology and hepatology,
H Deguchi, and Y Tabuchi, and Y Saitoh
January 1997, Oncology reports,
Copied contents to your clipboard!